Acquired by Boston Scientific in Oct 2024
SILK - Silk Road Medical, Inc
NASDAQ
->
Healthcare
->
Medical Devices
Sunnyvale,
United States
Type: Equity
SILK price evolution
SILK
| (in millions $) | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 | 30 Sep 2023 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $22.64 | $22.63 | $20.21 | $29.19 |
| Short term investments | $149.34 | $151.83 | $161.26 | $163.67 |
| Net receivables | $26.25 | $27.2 | $23.57 | $21.78 |
| Inventory | $29.68 | $30.49 | $29.88 | $22.07 |
| Total current assets | $241.02 | $235.69 | $240.84 | $240.98 |
| Long term investments | $14.18 | $2.03 | $9.46 | $4.35 |
| Property, plant & equipment | $8.38 | $8.09 | $8.11 | $8.34 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | $28.79 | $16.62 | $24.47 | $19.88 |
| Total investments | $163.52 | $153.86 | $170.72 | $168.02 |
| Total assets | $269.81 | $252.31 | $265.31 | $260.86 |
| Current liabilities | ||||
| Accounts payable | $3.69 | $2.97 | $5.68 | $5.09 |
| Deferred revenue | ||||
| Short long term debt | ||||
| Total current liabilities | $31.57 | $21.34 | $30.28 | $24.02 |
| Long term debt | $76.15 | $75.89 | $75.63 | $75.36 |
| Total noncurrent liabilities | $83.55 | $83.69 | $83.88 | $83.7 |
| Total debt | $76.15 | $75.89 | $75.63 | $75.36 |
| Total liabilities | $115.12 | $105.03 | $114.16 | $107.72 |
| Shareholders' equity | ||||
| Retained earnings | -$430.19 | -$413.59 | -$399.45 | -$386.44 |
| Other shareholder equity | -$0.12 | -$0.02 | $0.07 | -$0.28 |
| Total shareholder equity | $154.68 | $147.28 | $151.15 | $153.14 |
| (in millions $) | 31 Dec 2023 | 31 Jan 2023 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $20.21 | $55.51 | $110.46 | $69.78 |
| Short term investments | $161.26 | $158.32 | $78.02 | |
| Net receivables | $23.57 | $18.01 | $11.83 | $9.07 |
| Inventory | $29.88 | $19.29 | $17.85 | $9.99 |
| Total current assets | $240.84 | $254.9 | $143.33 | $173.33 |
| Long term investments | $9.46 | |||
| Property, plant & equipment | $8.11 | $14.45 | $7.7 | $2.84 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | $24.47 | $14.79 | $13.3 | $5.99 |
| Total investments | $170.72 | $158.32 | $78.02 | |
| Total assets | $265.31 | $269.69 | $156.63 | $179.31 |
| Current liabilities | ||||
| Accounts payable | $5.68 | $2.52 | $2.38 | $2.6 |
| Deferred revenue | ||||
| Short long term debt | $3.9 | |||
| Total current liabilities | $30.28 | $24.49 | $26.09 | $19.55 |
| Long term debt | $75.63 | $74.6 | $44.79 | $48.53 |
| Total noncurrent liabilities | $83.88 | $81.32 | $51.3 | $52.26 |
| Total debt | $75.63 | $74.6 | $48.69 | $48.53 |
| Total liabilities | $114.16 | $105.81 | $77.39 | $71.81 |
| Shareholders' equity | ||||
| Retained earnings | -$399.45 | -$343.71 | -$288.7 | -$238.89 |
| Other shareholder equity | $0.07 | -$0.17 | $0.04 | |
| Total shareholder equity | $151.15 | $163.88 | $79.24 | $107.5 |
| (in millions $) | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 | 30 Sep 2023 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $51.24 | $48.48 | $47.27 | $44.44 |
| Cost of revenue | $12.74 | $11.98 | $12.47 | $12.05 |
| Gross Profit | $38.51 | $36.5 | $34.8 | $32.38 |
| Operating activities | ||||
| Research & development | $11.88 | $10.66 | $10.06 | $10.05 |
| Selling, general & administrative | $43.82 | $40.77 | $39.11 | $36.01 |
| Total operating expenses | $55.7 | $51.44 | $49.17 | $46.06 |
| Operating income | -$17.2 | -$14.93 | -$14.37 | -$13.67 |
| Income from continuing operations | ||||
| EBIT | -$14.88 | -$12.41 | -$11.16 | -$11.01 |
| Income tax expense | ||||
| Interest expense | $1.73 | $1.72 | $1.73 | $1.73 |
| Net income | ||||
| Net income | -$16.6 | -$14.14 | -$12.89 | -$12.74 |
| Income (for common shares) | -$16.6 | -$14.14 | -$12.89 | -$12.74 |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $177.13 | $138.64 | $101.47 | $75.23 |
| Cost of revenue | $50.05 | $37.88 | $25.45 | $21.29 |
| Gross Profit | $127.09 | $100.76 | $76.03 | $53.94 |
| Operating activities | ||||
| Research & development | $41.32 | $36.45 | $27.11 | $21.27 |
| Selling, general & administrative | $145.03 | $116.32 | $96.39 | $75.52 |
| Total operating expenses | $186.36 | $152.77 | $123.5 | $96.8 |
| Operating income | -$59.27 | -$52 | -$47.47 | -$42.86 |
| Income from continuing operations | ||||
| EBIT | -$48.87 | -$50.08 | -$47.33 | -$42.95 |
| Income tax expense | ||||
| Interest expense | $6.87 | $5.1 | $2.52 | $4.41 |
| Net income | ||||
| Net income | -$55.74 | -$55.18 | -$49.85 | -$47.37 |
| Income (for common shares) | -$55.74 | -$55.18 | -$49.85 | -$47.37 |
| (in millions $) | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 | 30 Sep 2023 |
|---|---|---|---|---|
| Net income | -$16.6 | -$14.14 | -$12.89 | -$12.74 |
| Operating activities | ||||
| Depreciation | $0.95 | $0.93 | $0.93 | $0.93 |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $11.04 | $10.36 | $9.61 | $10.25 |
| Total cash flows from operations | -$3.38 | -$15.32 | -$8.45 | -$6.8 |
| Investing activities | ||||
| Capital expenditures | -$0.95 | -$0.39 | -$0.45 | -$0.33 |
| Investments | -$8.72 | $18.13 | -$1.13 | $7.79 |
| Total cash flows from investing | -$9.67 | $17.74 | -$1.58 | $7.46 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $13.07 | $1.05 | $0.13 | |
| Net borrowings | ||||
| Total cash flows from financing | $13.07 | $1.05 | $0.13 | |
| Effect of exchange rate | ||||
| Change in cash and equivalents | $0.01 | $2.42 | -$8.98 | $0.79 |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Net income | -$55.74 | -$55.18 | -$49.85 | -$47.37 |
| Operating activities | ||||
| Depreciation | $3.79 | $3.17 | $1.92 | $1.39 |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $38.89 | $25.02 | $14.61 | $7.23 |
| Total cash flows from operations | -$32.01 | -$32.58 | -$38.94 | -$42.07 |
| Investing activities | ||||
| Capital expenditures | -$1.51 | -$5 | -$4.76 | -$0.84 |
| Investments | -$5.67 | -$157.06 | $77.4 | -$8.55 |
| Total cash flows from investing | -$7.18 | -$162.07 | $72.64 | -$9.39 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $3.89 | $114.79 | $6.95 | $75.74 |
| Net borrowings | $24.91 | $6.01 | ||
| Total cash flows from financing | $3.89 | $139.7 | $6.98 | $81.75 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | -$35.3 | -$54.95 | $40.69 | $30.29 |
News
Fundamentals
| Market cap | $1.12B |
|---|---|
| Enterprise value | $1.17B |
| Shares outstanding | 40.61M |
| Revenue | $191.43M |
|---|---|
| EBITDA | -$45.73M |
| EBIT | -$49.46M |
| Net Income | -$56.37M |
| Revenue Q/Q | 13.12% |
| Revenue Y/Y | 17.53% |
| P/E ratio | -19.80 |
|---|---|
| EV/Sales | 6.11 |
| EV/EBITDA | -25.59 |
| EV/EBIT | -23.65 |
| P/S ratio | 5.83 |
| P/B ratio | 7.21 |
| Book/Share | 3.81 |
| Cash/Share | 0.56 |
| EPS | -$1.39 |
|---|---|
| ROA | -21.51% |
| ROE | -37.19% |
| Debt/Equity | 0.76 |
|---|---|
| Net debt/EBITDA | -2.02 |
| Current ratio | 7.63 |
| Quick ratio | 6.69 |